Valuation in Life Sciences: A Practical Guide
暫譯: 生命科學估值:實用指南

Boris Bogdan

  • 出版商: Springer
  • 出版日期: 2014-10-31
  • 售價: $2,860
  • 貴賓價: 9.5$2,717
  • 語言: 英文
  • 頁數: 384
  • 裝訂: Paperback
  • ISBN: 3642425844
  • ISBN-13: 9783642425844
  • 海外代購書籍(需單獨結帳)

相關主題

商品描述

Valuation is a hot topic among life sciences professionals. There is no clear understanding on how to use the different valuation approaches and how to determine input parameters. Some do not value at all, arguing that it is not possible to get realistic and objective numbers out of it. Some claim it to be an art. In the following chapters we will provide the user with a concise val- tion manual, providing transparency and practical insight for all dealing with valuation in life sciences: project and portfolio managers, licensing executives, business developers, technology transfer managers, entrep- neurs, investors, and analysts. The purpose of the book is to explain how to apply discounted cash flow and real options valuation to life sciences p- jects, i.e. to license contracts, patents, and firms. We explain the fun- mentals and the pitfalls with case studies so that the reader is capable of performing the valuations on his own and repeat the theory in the exercises and case studies. The book is structured in five parts: In the first part, the introduction, we discuss the role of the players in the life sciences industry and their p- ticular interests. We describe why valuation is important to them, where they need it, and the current problems to it. The second part deals with the input parameters required for valuation in life sciences, i.e. success rates, costs, peak sales, and timelines.

商品描述(中文翻譯)

估值是生命科學專業人士中的熱門話題。對於如何使用不同的估值方法以及如何確定輸入參數,並沒有明確的理解。有些人根本不進行估值,認為無法獲得現實和客觀的數字。有些人則聲稱這是一門藝術。在接下來的章節中,我們將為用戶提供一本簡明的估值手冊,為所有涉及生命科學估值的專業人士提供透明度和實用見解:項目和投資組合經理、授權高管、商業開發人員、技術轉移經理、企業家、投資者和分析師。本書的目的是解釋如何將折現現金流(discounted cash flow)和實際選擇權(real options)估值應用於生命科學項目,即授權合同、專利和公司。我們通過案例研究解釋基本原理和陷阱,使讀者能夠獨立進行估值,並在練習和案例研究中重複理論。本書分為五個部分:在第一部分引言中,我們討論生命科學行業中各參與者的角色及其特定利益。我們描述了為什麼估值對他們重要,他們在哪些方面需要估值,以及目前面臨的問題。第二部分則處理生命科學估值所需的輸入參數,即成功率、成本、峰值銷售和時間表。

最後瀏覽商品 (20)